Drug Profile
Telratolimod - Kindeva Drug Delivery/AstraZeneca
Alternative Names: Injectable 3M 052; MEDI-9197Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator 3M Drug Delivery Systems
- Developer AstraZeneca; MedImmune
- Class Amides; Antineoplastics; Imidazoles; Quinolines; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cutaneous T-cell lymphoma
- Discontinued Solid tumours
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma(Late-stage disease, Monotherapy) in Canada (Intratumoural, Injection)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma(Late-stage disease, Monotherapy) in France (Intratumoural, Injection)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Cutaneous-T-cell-lymphoma(Late-stage disease, Monotherapy) in USA (Intratumoural, Injection)